KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for West Pharmaceutical Services (WST) over the last 10 years, with Q3 2025 value amounting to $13.5 million.

  • West Pharmaceutical Services' Non-Current Deffered Revenue fell 1118.42% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 1118.42%. This contributed to the annual value of $15.4 million for FY2024, which is 1720.43% down from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Non-Current Deffered Revenue is $13.5 million, which was down 1118.42% from $12.5 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Non-Current Deffered Revenue peaked at $28.9 million during Q4 2021, and registered a low of $11.4 million during Q1 2025.
  • For the 5-year period, West Pharmaceutical Services' Non-Current Deffered Revenue averaged around $19.3 million, with its median value being $19.0 million (2023).
  • As far as peak fluctuations go, West Pharmaceutical Services' Non-Current Deffered Revenue surged by 2620.09% in 2021, and later tumbled by 3870.97% in 2025.
  • West Pharmaceutical Services' Non-Current Deffered Revenue (Quarter) stood at $28.9 million in 2021, then tumbled by 33.91% to $19.1 million in 2022, then dropped by 2.62% to $18.6 million in 2023, then decreased by 17.2% to $15.4 million in 2024, then dropped by 12.34% to $13.5 million in 2025.
  • Its Non-Current Deffered Revenue stands at $13.5 million for Q3 2025, versus $12.5 million for Q2 2025 and $11.4 million for Q1 2025.